Severe infusion-related reaction to crizanlizumab in an adolescent with sickle cell disease

Am J Hematol. 2020 Dec;95(12):E338-E339. doi: 10.1002/ajh.26002. Epub 2020 Sep 30.

Authors

Kristine Karkoska¹, Charles T Quinn^{1

2}, Kelly Clapp¹, Patrick T McGann^{1

2}

Affiliations

¹ Division of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
² Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio.

PMID: 32945013
DOI: 10.1002/ajh.26002

No abstract available

Publication types

Case Reports
Clinical Trial, Phase II
Letter
Multicenter Study
Randomized Controlled Trial

MeSH terms

Adolescent
Adult
Aged
Anemia, Sickle Cell / drug therapy*
Antibodies, Monoclonal, Humanized* / administration & dosage
Antibodies, Monoclonal, Humanized* / adverse effects
Female
Humans
Male
Middle Aged
Pain* / chemically induced
Pain* / drug therapy

Substances

Antibodies, Monoclonal, Humanized
crizanlizumab